课题基金 / 基金详情

University of Hawaii Cancer Center CCSG

University of Hawaii Cancer Center CCSG
夏威夷大学癌症中心 CCSG
批准号:
10837568
负责人:
Naoto T Ueno
金额:
$219.1万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-05-05 至 2024-06-30

项目摘要

项目成果

Naoto T Ueno的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 夏威夷大学癌症中心(UHCC)的使命是通过 研究,教育,病人护理和社区外展,重点是独特的种族,文化和 夏威夷和太平洋的环境特征。为了完成这一使命,UHCC组织为 两个癌症研究项目:太平洋人口科学(PSP)和癌症生物学(CB)。 每个项目都有两个组成部分,包括对基本机制和病因学的研究。 癌症的目标和干预措施,以便将发现转化为它所服务的人群。内 其计划,UHCC有一个强大的癌症研究基础,超过1500万美元的同行评审资金, 其中68%来自NCI。PSP有24名正式成员,CB有18名正式成员,他们都是高级别的。 协作,方案内和方案间以及机构间研究的比例很高 合作和出版物。为了促进研究目标的成功实现,UHCC支持五个 共享资源:生物统计学、基因组学和生物信息学、分析生物化学、营养学 支持和代谢组学。UHCC服务于夏威夷独特的种族多样的集水区, 太平洋和自然资源丰富的独特环境。这推动了UHCC对种族多样性的关注, 癌症与研究和社区参与,旨在解决重大癌症健康问题 包括夏威夷原住民在内的特定人群之间的差异。研究项目,社区教育, 公共卫生和临床试验干预措施针对集水区的重要癌症, 基础研究包括对环境中的化合物进行评价,以用于药物发现研究。一 建立了一个独特的、基于社区网络的临床研究企业,通过该企业,UHCC 为超过70%的夏威夷人口提供癌症临床试验;这部分得到了 UHCC领导的三个相互竞争的卫生系统的联盟,作为支持UHCC的合作企业。癌 太平洋地区的预防活动与关岛大学和其他机构合作, 对癌症控制的影响,并导致了由UHCC领导的跨太平洋癌症伙伴关系的形成 预防UHCC在该地区的重要性体现在其对癌症控制的重大影响上 国家癌症政策。夏威夷大学(UH)在UHCC上进行了大量投资。 随着新主任的招聘,呃重申主任对教师任命的直接权力, 事务,中心预算和运营,以及187,000平方米的空间分配。英尺癌症中心大楼的 大学、州长和州政府为行动提供了更多的财政支持,并授权 许多教师招聘,以加强现有的计划,并着手新的举措,通过通知 UHCC战略规划过程,以支持其减少癌症负担的使命。
英文摘要
ABSTRACT The mission of the University of Hawai‘i Cancer Center (UHCC) is to reduce the burden of cancer through research, education, patient care and community outreach with an emphasis on the unique ethnic, cultural and environmental characteristics of Hawai‘i and the Pacific. To accomplish this mission, UHCC is organized into two cancer research programs: Population Sciences in the Pacific (PSP) and Cancer Biology (CB). Programs are each organized with two components spanning the study of basic mechanism and etiologies of cancer to addressing targets and interventions in order to translate discovery to the population it serves. Within its programs, UHCC has a strong foundation of cancer research with over $15 million in peer-reviewed funding, 68% of which is from the NCI. PSP has 24 full members and CB has 18 full members who are highly collaborative as evidenced by a high percentage of intra- and inter-programmatic, and inter-institutional, research collaborations and publications. To facilitate successful attainment of research goals, UHCC supports five shared resources: Biostatistics, Genomics and Bioinformatics, Analytical Biochemistry, Nutrition Support, and Metabolomics. UHCC serves a unique ethnically diverse catchment area in Hawai‘i and the Pacific and a unique environment rich in natural resources. This drives UHCC’s focus on ethnic diversity and cancer and research and community engagement directed toward addressing significant cancer health disparities among specific populations, including Native Hawaiians. Research programs, community education, public health and clinical trial interventions are targeted toward cancers of importance in the catchment area and basic investigations include evaluation of compounds from the environment for drug discovery research. A unique, community-network based clinical research enterprise has been established through which UHCC provides access to cancer clinical trials for over 70% of the Hawai‘i population; this is supported in part by a UHCC-led affiliation of three competing health systems as a cooperative venture supporting UHCC. Cancer prevention activities across the Pacific, in collaboration with the University of Guam and others, have had major impact on cancer control and have led to the formation of the UHCC-led Trans-Pacific Partnership for Cancer Prevention. The importance of UHCC in the region is exemplified by its significant impact on cancer control legislation and State cancer policy. The University of Hawai‘i (UH) has made significant investments in UHCC. With the recruitment new Director, UH reaffirmed the Director’s direct authority over faculty appointments and affairs, Center budget and operations, and space allocation in the 187,000 sq. ft. Cancer Center building. The University, Governor and State have provided increased financial support for operations and authorized numerous faculty recruitments to strengthen existing programs and embark on new initiatives informed through the UHCC strategic planning process in support of its mission to reduce the burden of cancer.
期刊论文(798)
专著(0)
科研奖励(0)
会议论文
Diet Quality of Young Children in the US-Affiliated Pacific's Children's Healthy Living (CHL) Program.
美国附属太平洋儿童健康生活 (CHL) 计划中幼儿的饮食质量。
DOI: 10.1016/j.jand.2023.08.003
发表时间: 2023
期刊: Journal of the Academy of Nutrition and Dietetics
影响因子: 4.8
作者: [DelaCruz,Rica, Novotny,Rachel, Wilkens,LynneR, Shvetsov,YuriiB, Yamanaka,AshleyB, Butel,Jean, Aflague,TanishaF, Coleman,Patricia, Shallcross,Leslie, Deenik,Jonathan, Mapa,VictoriaLeeR, Boushey,CarolJ, Fleming,Travis]
通讯作者: Fleming,Travis
Cholangiocarcinoma in Pacific Islanders Compared to Asians.
太平洋岛民的胆管癌与亚洲人的比较。
DOI: --
发表时间: 2021
期刊: Hawai'i journal of health & social welfare
影响因子: --
作者: [Shiosaki,JessicaR, Sempokuya,Tomoki, Hernandez,BrendaY, Wong,LindaL]
通讯作者: Wong,LindaL
A Dietary Supplement Frequency Questionnaire Correctly Ranks Nutrient Intakes in US Older Adults When Compared to a Comprehensive Dietary Supplement Inventory.
与综合膳食补充剂清单相比,膳食补充剂频率调查问卷正确地对美国老年人的营养摄入量进行了排名。
DOI: 10.1093/jn/nxab140
发表时间: 2021
期刊: The Journal of nutrition
影响因子: --
作者: [Steffen,AlanaD, Wilkens,LynneR, Yonemori,KimM, Albright,CherylL, Murphy,SuzanneP]
通讯作者: Murphy,SuzanneP
DOI: 10.1183/13993003.01815-2019
发表时间: 2021-01
期刊: The European respiratory journal
影响因子: --
作者: [Wills TA, Soneji SS, Choi K, Jaspers I, Tam EK]
通讯作者: Tam EK
共 513 条
    Developing a novel combination immunotherapy for triple-negative breast cancer
    • 批准号:
      10734197
    • 项目类别:
    • 资助金额:
      $66.49万
    • 财政年份:
      2023
    • 负责人:
      Naoto T Ueno
    • 依托单位:
    Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
    • 批准号:
      10836263
    • 项目类别:
    • 资助金额:
      $58.15万
    • 财政年份:
      2022
    • 负责人:
      Naoto T Ueno
    • 依托单位:
    Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
    Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
    海外基金